Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether giving a drug called PCK3145 can reduce the
level of a protein in the blood called MMP-9 as well as to find out how long the drug will
remain in your system over time. This drug has been tested previously in prostate cancer
patients abroad and has been shown to be safe with minimal side effects. However, we do not
know whether changes in MMP-9 levels correlate with tumor shrinkage or symptom improvement.
We would also like to evaluate the potential pain relief (analgesic) effect of PCK3145 at
15mg/m² i.v. weekly for 12 weeks on patients with both symptomatic and asymptomatic castrate
metastatic prostate cancer who are dependent on opioid analgesics. We would also like to
monitor pain through a brief pain questionaire, and determine the impact on markers of bone
turnover.